On May 5, 2026 Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, reported its interim results for the first quarter of 2026 and provided a business update.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"During the first quarter of 2026, we continued to execute against our strategic priorities in a challenging biotech environment. We strengthened the clinical and translational foundation of mitazalimab through new data presentations, while maintaining clear focus on advancing the program toward late‑stage development under disciplined strategic and financial conditions. In parallel, HLX22 progress in our external portfolio, supports additional long‑term value potential without development cost exposure for Alligator."
Søren Bregenholt, CEO of Alligator Bioscience
BUSINESS UPDATE
Mitazalimab
Additional data dissemination: Updated and final outcomes data from the OPTIMIZE 1 study were presented at the ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium 2026, further strengthening the clinical and translational foundation of the program.
Continued scientific visibility: New data from an investigator initiated trial evaluating mitazalimab were accepted for presentation at the AACR (Free AACR Whitepaper) Annual Meeting 2026, providing additional insight into the antibody’s mechanism of action and tumor directed immune activation.
Technology
Strengthened intellectual property position: Alligator strengthened the intellectual property protection for its bispecific antibody technology RUBY, reinforcing the scientific and commercial foundation for future pipeline development and partnering opportunities.
HLX22
Progress in partnered development: The first patient was dosed in Henlius’ Phase 2/3 study of HLX22 in recurrent breast cancer, marking an additional step in the late stage development of the program.
Company / Financial position
Capital structure updates following the rights issue: Alligator announced the outcome of the exercise of warrants of series TO 14, resulting in gross proceeds of approximately 19 MSEK and changes in the number of shares and votes, as well as related directed issues to guarantors and Fenja Capital, in accordance with previously communicated terms. Alligator’s management further announced their intention to subscribe pro rata in the TO 14 warrant program, aligning management interests with those of shareholders.
Nomination Committee proposal ahead of the AGM: The Nomination Committee presented its proposal for the Board of Directors ahead of the Annual General Meeting, including the nomination of two new Board members.
FINANCIAL SUMMARY FOR Q1 2026
The financial summaries for the quarterly periods ending 31 March 2026 and 31 March 2025 are presented below.
All amounts in MSEK,
unless specified January – March 2026 January – March 2025
Net sales - -
Operating profit/loss -17.8 -43.7
Profit/loss for the period 1.4 -8.3
Cash flow for the period -29.1 -34.6
Cash and cash equivalents 33.0 28.9
Earnings per share before and after dilution*, SEK 0.0 -1.1
* Adjusted for reverse share split in 2025.
The full report is attached as a PDF, and is also available on the company’s website: View Source
Alligator will host a webinar on Tuesday, 5 May 2026, at 1 p.m. CEST/ 7 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report, which will be followed by a Q&A session.
(Press release, Alligator Bioscience, MAY 5, 2026, View Source [SID1234665102])